High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Persistent/Relapsed Ovarian Cancer.
- Author:
So Eun KIM
1
;
Jong Ho WON
;
Hyun Soo KIM
;
Joon Sung PARK
;
Chan Kyu KIM
;
Kyu Taeg LEE
;
Sung Kyu PARK
;
Seung Ho BAICK
;
Dae Sik HONG
;
Hee Sook PARK
;
Hugh Chul KIM
Author Information
1. Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea. jhwon@hosp.sch.ac.kr
- Publication Type:Original Article
- Keywords:
Ovarian neoplasm;
High dose chemotherapy;
Stem cell transplantation
- MeSH:
Autografts;
Bacteremia;
Disease-Free Survival;
Drug Therapy*;
Fever;
Hematopoietic Stem Cell Transplantation;
Hospitals, University;
Humans;
Korea;
Ovarian Neoplasms*;
Peripheral Blood Stem Cell Transplantation*;
Retrospective Studies;
Stem Cell Transplantation
- From:Cancer Research and Treatment
2002;34(6):439-443
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: High dose chemotherapy (HDC) is increasingly being used for ovarian cancer. Although early studies of autotransplantation for advanced ovarian cancer have been encouraging, most reported series were small, and no randomized trials have been reported. HDC and autologous hematopoietic stem cell transplantation were rarely performed in patients with ovarian cancer in Korea, and no results have been reported with the exception of one case report. MATERIALS AND METHODS: We retrospectively analyzed 10 patients with refractory or relapsed ovarian cancer having received HDC and autologous peripheral blood stem cell transplantation (APBSCT), between January 1996 and September 1998, at the Soon Chun Hyang and Ajou University Hospitals. RESULTS: Ten patients were treated with HDC and APBSCT. Six patients achieved complete response (CR) and 1 a partial response (PR), with a response rate of 70%. Three patients did not respond following mobilization chemotherapy, and failed to respond after HDC. The median duration of progression free survival (PFS) and overall survival (OS) were 6 (4~46) and 13 (3~50+) months, respectively. The median duration of OS of the responders following mobilization chemotherapy was 23 (8~50+) compared with 12 (3~18) months of the non- responders. With regard to the treatment related toxicity, 8 patients had neutropenic fevers, and bacteremia was documented in 4. The non-hematological toxicities were never life threatening, and there were no treatment related deaths. CONCLUSION: HDC, followed by APBSCT, is well-tolerated patients with refractory or relapsed ovarian cancer, and following mobilization chemotherapy the responders survived longer than the non-responders.
